Mersana Therapeutics's total assets for Q2 2025 were $84.57M, a decrease of -24.80% from the previous quarter. MRSN total liabilities were $137.72M for the fiscal quarter, a -3.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.